- Home
- ACV vs AVIR Comparison
ACV vs AVIR Comparison
Compare ACV & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACV | AVIR |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.3M | 236.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACV | AVIR |
|---|---|---|
| Price | $26.19 | $3.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 38.8K | ★ 415.4K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.82 | $2.46 |
| 52 Week High | $23.74 | $4.02 |
Technical Indicators
Market Signals| Indicator | ACV | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 53.39 |
| Support Level | $26.05 | $2.99 |
| Resistance Level | $26.76 | $3.24 |
| Average True Range (ATR) | 0.44 | 0.09 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 63.98 | 80.65 |
Price Performance
Historical ComparisonAbout ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).